NeuBase Therapeutics Received A Notice On April 4, 2024 From The Listing Qualifications Department Of The Nasdaq Stock Market Notifying The Company That It Was Not In Compliance With Nasdaq's Continued Listing Requirements Under Nasdaq Listing Rule 5250(c)(1)
Portfolio Pulse from Benzinga Newsdesk
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) received a notice from Nasdaq on April 4, 2024, for not complying with the continued listing requirements due to its failure to timely file its Annual Report for the fiscal year ended December 31, 2023. The company has until June 3, 2024, to submit a compliance plan, with a potential extension until September 30, 2024, to regain compliance.
April 05, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NeuBase Therapeutics received a non-compliance notice from Nasdaq for not filing its Annual Report on time, risking its listing status.
Receiving a non-compliance notice from Nasdaq significantly impacts investor confidence and can lead to a negative perception of the company's financial health and governance, likely resulting in a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100